159 related articles for article (PubMed ID: 35904861)
1. HPV type-specific trends in cervical precancers in the United States, 2008 to 2016.
Gargano JW; McClung N; Lewis RM; Park IU; Whitney E; Castilho JL; Pemmaraju M; Niccolai LM; Brackney M; DeBess E; Ehlers S; Bennett NM; Scahill M; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
Int J Cancer; 2023 Jan; 152(2):137-150. PubMed ID: 35904861
[TBL] [Abstract][Full Text] [Related]
2. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
4. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States.
Hariri S; Johnson ML; Bennett NM; Bauer HM; Park IU; Schafer S; Niccolai LM; Unger ER; Markowitz LE;
Cancer; 2015 Aug; 121(16):2775-81. PubMed ID: 26098295
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States.
Saadeh K; Park I; Gargano JW; Whitney E; Querec TD; Hurley L; Silverberg M
Vaccine; 2020 Jan; 38(1):39-45. PubMed ID: 31611099
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study.
Sánchez-Lander J; Cortiñas P; Loureiro CL; Pujol FH; Medina F; Capote-Negrín L; Bianchi G; García-Barriola V; Ruiz-Benni A; Avilán-Rovira J; Acosta H
Cancer Epidemiol; 2012 Oct; 36(5):e284-7. PubMed ID: 22608058
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
8. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
9. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.
Hariri S; Bennett NM; Niccolai LM; Schafer S; Park IU; Bloch KC; Unger ER; Whitney E; Julian P; Scahill MW; Abdullah N; Levine D; Johnson ML; Steinau M; Markowitz LE;
Vaccine; 2015 Mar; 33(13):1608-13. PubMed ID: 25681664
[TBL] [Abstract][Full Text] [Related]
10. HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States.
Hariri S; Unger ER; Schafer S; Niccolai LM; Park IU; Bloch KC; Bennett NM; Steinau M; Johnson ML; Markowitz LE;
Cancer Epidemiol Biomarkers Prev; 2015 Feb; 24(2):393-9. PubMed ID: 25416715
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J-HERS 2021 multicenter study.
Saeki Y; Saito M; Irie T; Itoh F; Enatsu A; Komura H; Fujii M; Fujii R; Hidaka N; Maehama T; Shirasu N; Waseda T; Shibata T; Takada E; Mibe K; Sakamoto J; Yamada S; Takakura M; Sasagawa T
J Med Virol; 2024 Feb; 96(2):e29413. PubMed ID: 38314927
[TBL] [Abstract][Full Text] [Related]
12. Reduction in HPV16/18 prevalence among young women with high-grade cervical lesions following the Japanese HPV vaccination program.
Matsumoto K; Yaegashi N; Iwata T; Yamamoto K; Aoki Y; Okadome M; Ushijima K; Kamiura S; Takehara K; Horie K; Tasaka N; Sonoda K; Takei Y; Aoki Y; Konnai K; Katabuchi H; Nakamura K; Ishikawa M; Watari H; Yoshida H; Matsumura N; Nakai H; Shigeta S; Takahashi F; Noda K; Yoshikawa H;
Cancer Sci; 2019 Dec; 110(12):3811-3820. PubMed ID: 31596999
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China.
Xiao M; Xu Q; Li H; Gao H; Bie Y; Zhang Z
Medicine (Baltimore); 2016 Jan; 95(3):e2555. PubMed ID: 26817906
[TBL] [Abstract][Full Text] [Related]
14. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.
Haupt RM; Wheeler CM; Brown DR; Garland SM; Ferris DG; Paavonen JA; Lehtinen MO; Steben M; Joura EA; Giacoletti KE; Radley DR; James MK; Saah AJ; Sings HL;
Int J Cancer; 2011 Dec; 129(11):2632-42. PubMed ID: 21491420
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer.
Onuki M; Matsumoto K; Satoh T; Oki A; Okada S; Minaguchi T; Ochi H; Nakao S; Someya K; Yamada N; Hamada H; Yoshikawa H
Cancer Sci; 2009 Jul; 100(7):1312-6. PubMed ID: 19432906
[TBL] [Abstract][Full Text] [Related]
16. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.
Ault KA;
Lancet; 2007 Jun; 369(9576):1861-1868. PubMed ID: 17544766
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic human papillomavirus-infected immature metaplastic cells and cervical neoplasia.
van der Marel J; van Baars R; Alonso I; del Pino M; van de Sandt M; Lindeman J; ter Harmsel B; Boon M; Smedts F; Ordi J; Torné A; Jenkins D; Quint W
Am J Surg Pathol; 2014 Apr; 38(4):470-9. PubMed ID: 24503756
[TBL] [Abstract][Full Text] [Related]
18. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
19. Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015.
Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Johnson Jones ML; Whitney E; Pemmaraju M; Brackney M; Abdullah N; Scahill M; Dahl RM; Cleveland AA; Unger ER; Markowitz LE;
Clin Infect Dis; 2019 Apr; 68(8):1282-1291. PubMed ID: 30137283
[TBL] [Abstract][Full Text] [Related]
20. Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016.
McClung NM; Gargano JW; Park IU; Whitney E; Abdullah N; Ehlers S; Bennett NM; Scahill M; Niccolai LM; Brackney M; Griffin MR; Pemmaraju M; Querec TD; Cleveland AA; Unger ER; Markowitz LE;
MMWR Morb Mortal Wkly Rep; 2019 Apr; 68(15):337-343. PubMed ID: 30998672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
